First Pacific Advisors Wins Big With Its Nexeo Solutions Inc. (NXEO) Bet

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Schedule 13D

CUSIP No. 65342H102

Amendment No. 3 to Schedule 13D

The following constitutes Amendment No. 3 (Amendment No. 3) to the Schedule 13D filed with the Securities and Exchange Commission (the
SEC) by First Pacific Advisors, LLC, FPA Crescent Fund, a series of FPA Funds Trust, FPA Global Opportunity Fund, a series of FPA Hawkeye Fund, LLC, FPA Select Drawdown Fund, L.P., FPA Select Fund, a series of FPA Hawkeye Fund, LLC, FPA
Value Partners Fund, a series of FPA Hawkeye Fund, LLC, J. Richard Atwood, Steven T. Romick, Brian A. Selmo, and Mark Landecker on June 20, 2016, as amended by Amendment No. 1 filed on August 24, 2017, and Amendment No. 2 filed
on September 20, 2017. This Amendment No. 3 amends and supplements the Schedule 13D as specifically set forth herein.

All capitalized terms
contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

ITEM 4. PURPOSE OF TRANSACTION

Item 4 of Schedule
13D is supplemented and superseded, as the case may be, as follows:

On September 17, 2018, Univar Inc. (Parent), Pilates Merger Sub I
Corp (Merger Sub I), Pilates Merger Sub II LLC (Merger Sub II) and the Issuer entered into an Agreement and Plan of Merger (the Merger Agreement), which, among other things, provides for the merger of Merger Sub I
with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent, upon the terms and subject to the conditions set forth in the Merger Agreement, followed by the merger of the surviving
corporation with and into Merger Sub II, with Merger Sub II continuing as the surviving company (together, the Mergers), upon the terms and subject to the conditions set forth in the Merger Agreement.

In connection with the Merger Agreement, on September 17, 2018, FPA, FPA Crescent Fund, FPA Global Opportunity, FPA Value Partners, FPA Select Drawdown,
FPA Select, FPA Select Maple, FPA Select II (collectively, the Sponsor Group) and Parent entered into a Sponsor Support Agreement (the Sponsor Support Agreement). Pursuant to the Sponsor Support Agreement, the Sponsor Group
agreed that promptly following the time at which the registration statement filed in connection with the Mergers becomes effective and in any event within 24 hours of such time, the Sponsor Group will cause a shareholder written consent to be
executed and delivered with respect to 22,015,301 shares of Common Stock beneficially owned by members of the Sponsor Group (the Written Consent Shares) in favor of the adoption of the Merger Agreement. The Sponsor Group also agreed,
until the delivery of such shareholder written consent, to use their respective best efforts to cause an additional 3,512,386 shares of Common Stock beneficially owned by the Sponsor Group to be transferred such that they are held directly on the
Issuers books in a manner that would permit them to be included in that shareholder written consent. Further, the Sponsor Group agreed that as promptly as practicable following the time at which the definitive consent solicitation statement is
mailed to the holders of the Issuers Common Stock for approval of the Merger Agreement, the Sponsor Group will use best efforts to cause the applicable custodians or intermediaries to deliver to the Issuer a duly executed affirmative written
consent in favor of the adoption of the Merger Agreement with respect to additional shares of Common Stock beneficially owned by members of the Sponsor Group up to a total of 25,527,687 shares of Common Stock when aggregated with the Written Consent
Shares (such aggregate amount, the Subject Shares).

Further, FPA agreed that from the date of the Sponsor Support Agreement until the
termination of the Sponsor Support Agreement in accordance with its terms (the Covered Period), at any meeting of the Issuers shareholders or in any other action proposed to be taken by written consent of the Issuers
shareholders, the Sponsor Group will appear (in person or by proxy) at such meeting and cause all of the Subject Shares to be counted as present thereat for purposes of calculating a quorum and shall affirmatively vote (or cause to be voted) all
such Subject Shares in favor of, or, if action is to be taken by written consent in lieu of a meeting, deliver to the Issuer a duly executed affirmative written consent in favor of (to the extent applicable), (i) the adoption of the Merger
Agreement, (ii) any proposal to adjourn the meeting to solicit additional proxies in favor of the adoption of the Merger Agreement and the approval of the Mergers if there are not sufficient votes to adopt the Merger Agreement and approve the
Mergers on the date on which the Issuers shareholder meeting is held, and (iii) any other action, proposal, transaction or agreement the approval of which is required to ensure the timely consummation of the Mergers provided that the
members of the Sponsor Group shall have no obligation to consent to or vote in favor of any action, proposal, transaction or agreement pursuant to this clause (iii) if the underlying action or transaction is not conditioned upon the occurrence
of the Closing (as defined in the Merger Agreement).

In addition, pursuant to the Sponsor Support Agreement, the Sponsor Group agreed not enter into any tender,
voting or other agreement or arrangement with any other person until the termination of the Sponsor Support Agreement, directly or indirectly, to vote, grant a proxy or power of attorney or give instructions with respect to the voting of the Subject
Shares in any manner that is inconsistent with the Sponsor Support Agreement or otherwise take any other action with respect to the Subject Shares that would reasonably be expected to materially restrict, limit or interfere with the performance by
the Sponsor Group of its obligations under the Sponsor Support Agreement or the transactions contemplated thereby, including the approval of the adoption of the Merger Agreement. The Sponsor Group also agreed that, until the termination of Sponsor
Support Agreement, it shall vote or cause to be voted (including by written consent) the Subject Shares against (a) the adoption or approval of (i) any Company Acquisition Proposal (as defined in the Merger Agreement), including any
Company Superior Proposal (as defined in the Merger Agreement), (ii) any action, omission, proposal, transaction or agreement to be taken, consummated or entered into by the Issuer that, if so taken, consummated or entered into by the Issuer would,
or would reasonably be expected to, result in (A) a breach by the Issuer of any covenant, representation, warranty or other obligation of the Issuer set forth in the Merger Agreement or (B) the failure of any of the conditions to the
obligations of Parent, Merger Sub I or Merger Sub II to consummate the Mergers and the other transactions contemplated by the Merger Agreement set forth in Article VII of the Merger Agreement and any other action, agreement or transaction involving
the Issuer that is intended, or would reasonably be expected, to impede, interfere with, delay, postpone, adversely affect or prevent the consummation of the Mergers or the other transactions contemplated by the Merger Agreement. Further, each
member of the Sponsor Group agreed that during the Covered Period it will not, and will cause its directors, officers and employees not to, and will instruct and use its commercially reasonable efforts to cause its representatives not to, directly
or indirectly, (i) solicit, initiate, knowingly encourage or knowingly facilitate any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Company Acquisition Proposal (as defined in
the Merger Agreement); (ii) participate in any discussions or negotiations with any person regarding any Company Acquisition Proposal; (iii) approve or recommend, or publicly propose to approve or recommend, any Company Acquisition Proposal; or
(iv) enter into any Company Alternative Acquisition Agreement (as defined in the Merger Agreement).

The members of the Sponsor Group also agreed
that other than a transfer to an affiliate that signs a joinder to the Sponsor Support Agreement, during the Covered Period, the members of the Sponsor Group will not permit or allow any of the Subject Shares to be, and will cause the Subject Shares
not to be, directly or indirectly, (i) transferred, and will not make any offer or enter into any agreement providing for a transfer of any of the Subject Shares and will not commit to do, consent to, or otherwise facilitate any of the
foregoing, or (ii) deposited into a voting trust or become subject to a voting agreement or arrangement or a grant of a proxy or power of attorney (other than pursuant to the Sponsor Support Agreement).

The Sponsor Support Agreement will terminate if the Merger Agreement is terminated or in the event of certain amendments or waivers of the Merger Agreement,
including amendments or waivers that diminish the Merger Consideration (as defined in the Merger Agreement) or otherwise materially and adversely affects the rights of the Written Consent Parties (as defined in the Merger Agreement), including the
Sponsor Group.

The foregoing description of the Sponsor Support Agreement does not purport to be complete and is qualified in its entirety by reference
to the full text of the Sponsor Support Agreement, which is filed as Exhibit 99.1 and is incorporated herein by reference.

The Reporting Persons
continuously assess the Issuers business, financial condition, results of operations and prospects, general economic conditions, other developments and additional investment opportunities. Depending on such assessments, the Reporting Persons
may, subject to any limitations in the Sponsor Support Agreement, acquire additional securities of the Issuer or new securities of the Issuer, engage in any hedging or similar transactions with respect to the Issuers securities, or may
determine to sell or otherwise dispose of all or some of the Issuers securities in the open market, as applicable, in privately negotiated transactions, in transactions directly with the Issuer or otherwise. Such actions will depend upon a
variety of factors, including, without limitation, current and anticipated future trading prices, the financial condition, results of operations and prospects of the Issuer, alternative investment opportunities, general economic, financial market
and industry conditions and other factors that the Reporting Persons may deem material to their investment decision.

Going forward, the Reporting Persons
may engage in communications with one or more officers, members of Board, representatives, shareholders of the Issuer and other relevant parties regarding the Issuers business and certain initiatives, which could include one or more of the
items in subsections (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with
respect thereto.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 of this Schedule 13D is hereby amended and restated in its entirety as follows:

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference.

Set forth below is the aggregate number of shares of Common Stock directly held, as of the date hereof, by each of the following FPA investment advisory
clients and by WLRS Fund.

As the investment adviser
of FPA Crescent Fund, the Managed Accounts and the Private Investment Funds (collectively, the FPA Clients), FPA may be deemed to share voting and/or investment power over the securities of the Issuer held by the FPA Clients and
therefore may be deemed to beneficially own such securities. In addition, as the investment adviser to members of WLRS Fund, FPA may be deemed to share investment power over the securities of the Issuer held by WLRS Fund due such members
approval right with respect to transfers of the securities of the Issuer held by WLRS Fund, and therefore FPA may be deemed to beneficially own such securities.

As members of WLRS Fund, FPA Crescent Fund and the Managed Accounts may also be deemed to share investment
power over the securities of the Issuer held by WLRS Fund due to such approval right, and therefore FPA Crescent Fund and the Managed Accounts may be deemed to beneficially own such securities. Each member of WLRS Fund may elect at any time by
written notice to the Manager of WLRS Fund to receive a distribution of LLC Founder Shares and LLC Exchange Shares up to such members pro rata portion of its respective membership percentage.

(c) There have been no transactions in securities of the Issuer during the 60 days prior to the date hereof by any of the Reporting Persons.

(d) The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated by reference herein. The
limited partners of (or investors in) each of the FPA Clients for which FPA acts as general partner, managing member and/or investment adviser have the right to participate in the receipt of dividends from, or proceeds from the sale of, the shares
of Common Stock held for the accounts of their respective funds in accordance with their respective limited partnership interests (or investment percentages) in their respective funds.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS,
UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

Item 6 of Schedule 13D is supplemented and superseded, as the case may be, as
follows:

The disclosure in Item 4 is incorporated herein by reference.

The Sponsor Support Agreement is filed as Exhibit 99.1 to this Schedule 13D and is incorporated herein by reference.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is
true, complete and correct.

Dated as of September 18, 2018